BHCM
CBIO icon

Brevan Howard Capital Management’s Crescent Biopharma CBIO Stock Holding History

Brevan Howard Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,530
Closed -$359K – 2258
2026
Q1 		$359K Buy
+19,530
New +$224K ﹤0.01% 1504
2024
Q2 		– Sell
-233
Closed -$70K – 1177
2024
Q1 		$70K Buy
+233
New +$69.6K ﹤0.01% 921

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Brevan Howard Capital Management's CBIO Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 19,530 shares — an estimated $359K sold.

Brevan Howard Capital Management first reported a position in CBIO in Q1 2024 and held it in 2 quarters. The position peaked at $359K in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 19,530 Crescent Biopharma shares in Q2 2026, an estimated $359K.
  • Brevan Howard Capital Management first reported a position in Crescent Biopharma in Q1 2024 and held it in 2 quarters.
  • Brevan Howard Capital Management's Crescent Biopharma position peaked at $359K in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.